These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 33167509)

  • 1. Performance and Stability of Tenofovir Alafenamide Formulations within Subcutaneous Biodegradable Implants for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Johnson LM; Krovi SA; Demkovich ZR; van der Straten A
    Pharmaceutics; 2020 Nov; 12(11):. PubMed ID: 33167509
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of a Reservoir-Style Implant for Sustained Release of Tenofovir Alafenamide (TAF) for HIV Pre-Exposure Prophylaxis (PrEP).
    Johnson LM; Krovi SA; Li L; Girouard N; Demkovich ZR; Myers D; Creelman B; van der Straten A
    Pharmaceutics; 2019 Jul; 11(7):. PubMed ID: 31277461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trans-urocanic acid enhances tenofovir alafenamide stability for long-acting HIV applications.
    Sizovs A; Pons-Faudoa FP; Malgir G; Shelton KA; Bushman LR; Chua CYX; Anderson PL; Nehete PN; Sastry KJ; Grattoni A
    Int J Pharm; 2020 Sep; 587():119623. PubMed ID: 32663582
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Polymer Blending on the Performance of a Subcutaneous Biodegradable Implant for HIV Pre-Exposure Prophylaxis (PrEP).
    Li L; Areson C; van der Straten A; Johnson LM
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34207212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Tunable, Biodegradable, Thin-Film Polymer Device as a Long-Acting Implant Delivering Tenofovir Alafenamide Fumarate for HIV Pre-exposure Prophylaxis.
    Schlesinger E; Johengen D; Luecke E; Rothrock G; McGowan I; van der Straten A; Desai T
    Pharm Res; 2016 Jul; 33(7):1649-56. PubMed ID: 26975357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Pharmacokinetics and Local Tolerance of Tenofovir Alafenamide (TAF) From Subcutaneous Implant in Rabbits, Dogs, and Macaques.
    Gatto GJ; Krovi A; Li L; Massud I; Holder A; Gary J; Mills P; Mitchell J; Luecke E; Demkovich ZR; Heneine W; García-Lerma JG; Marzinke MA; Brand RM; Dobard CW; Johnson LM; Van Der Straten A
    Front Pharmacol; 2022; 13():923954. PubMed ID: 35928266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in local tissue microenvironment in response to subcutaneous long-acting delivery of tenofovir alafenamide in rats and non-human primates.
    Pons-Faudoa FP; Di Trani N; Capuani S; Hernandez N; Wood AM; Nehete B; Niles J; Shelton KA; Kezar S; Bushman LR; Chua CYX; Ittmann MM; Anderson PL; Nehete PN; Arduino RC; Nichols JE; Grattoni A
    J Control Release; 2023 Jun; 358():116-127. PubMed ID: 37120032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical Considerations for Long-acting Delivery of Tenofovir Alafenamide from Subdermal Implants for HIV Pre-exposure Prophylaxis.
    Gunawardana M; Remedios-Chan M; Sanchez D; Fanter R; Webster S; Webster P; Moss JA; Trinh M; Beliveau M; Ramirez CM; Marzinke MA; Kuo J; Gallay PA; Baum MM
    Pharm Res; 2023 Jul; 40(7):1657-1672. PubMed ID: 36418671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling.
    Rajoli RKR; Demkovich ZR; Flexner C; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2020 Jul; 64(8):. PubMed ID: 32423957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-acting biodegradable implant for sustained delivery of antiretrovirals (ARVs) and hormones.
    Li L; Gatto GJ; Brand RM; Krovi SA; Cottrell ML; Norton C; van der Straten A; Johnson LM
    J Control Release; 2021 Dec; 340():188-199. PubMed ID: 34678316
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fully synthetic injectable depots with high drug content and tunable pharmacokinetics for long-acting drug delivery.
    Ho DK; LeGuyader C; Srinivasan S; Roy D; Vlaskin V; Chavas TEJ; Lopez CL; Snyder JM; Postma A; Chiefari J; Stayton PS
    J Control Release; 2021 Jan; 329():257-269. PubMed ID: 33217474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design of a Drug-Eluting Subcutaneous Implant of the Antiretroviral Tenofovir Alafenamide Fumarate.
    Simpson SM; Widanapathirana L; Su JT; Sung S; Watrous D; Qiu J; Pearson E; Evanoff A; Karunakaran D; Chacon JE; Kiser PF
    Pharm Res; 2020 Apr; 37(4):83. PubMed ID: 32296951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanoencapsulation introduces long-acting phenomenon to tenofovir alafenamide and emtricitabine drug combination: A comparative pre-exposure prophylaxis efficacy study against HIV-1 vaginal transmission.
    Mandal S; Kang G; Prathipati PK; Zhou Y; Fan W; Li Q; Destache CJ
    J Control Release; 2019 Jan; 294():216-225. PubMed ID: 30576746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Concept Evaluation Study of a New Combination Bictegravir plus Tenofovir Alafenamide Nanoformulation with Prolonged Sustained-Drug-Release Potency for HIV-1 Preexposure Prophylaxis.
    Mandal S; Prathipati PK; Sunagawa SW; Destache CJ
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33526487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 28-Day Toxicity Study of Tenofovir Alafenamide Hemifumarate by Subcutaneous Infusion in Rats and Dogs.
    Zane D; Roller S; Shelton J; Singh R; Jain R; Wang Y; Yang B; Felx M; Alessi T; Feldman PL
    Microbiol Spectr; 2021 Sep; 9(1):e0033921. PubMed ID: 34190595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of long-acting tenofovir alafenamide (GS-7340) subdermal implant for HIV prophylaxis.
    Gunawardana M; Remedios-Chan M; Miller CS; Fanter R; Yang F; Marzinke MA; Hendrix CW; Beliveau M; Moss JA; Smith TJ; Baum MM
    Antimicrob Agents Chemother; 2015 Jul; 59(7):3913-9. PubMed ID: 25896688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-Focused Selection of PrEP Medication for Individuals at Risk of HIV: A Narrative Review.
    Fields SD; Tung E
    Infect Dis Ther; 2021 Mar; 10(1):165-186. PubMed ID: 33569743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urine Assay to Measure Tenofovir Concentrations in Patients Taking Tenofovir Alafenamide.
    Lalley-Chareczko L; Hiserodt E; Moorthy G; Zuppa A; Mounzer K; Koenig H
    Front Pharmacol; 2020; 11():286. PubMed ID: 32265700
    [No Abstract]   [Full Text] [Related]  

  • 19. Preventive efficacy of a tenofovir alafenamide fumarate nanofluidic implant in SHIV-challenged nonhuman primates.
    Pons-Faudoa FP; Sizovs A; Shelton KA; Momin Z; Niles JA; Bushman LR; Xu J; Chua CYX; Nichols JE; Demaria S; Ittmann MM; Hawkins T; Rooney JF; Marzinke MA; Kimata JT; Anderson PL; Nehete PN; Arduino RC; Ferrari M; Sastry KJ; Grattoni A
    Adv Ther (Weinh); 2021 Mar; 4(3):. PubMed ID: 33997267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single dose topical inserts containing tenofovir alafenamide fumarate and elvitegravir provide pre- and post-exposure protection against vaginal SHIV infection in macaques.
    Dobard CW; Peet MM; Nishiura K; Holder A; Dinh C; Mitchell J; Khalil G; Pan Y; Singh ON; McCormick TJ; Agrahari V; Gupta P; Jonnalagadda S; Heneine W; Clark MR; García-Lerma JG; Doncel GF
    EBioMedicine; 2022 Dec; 86():104361. PubMed ID: 36423375
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.